Researchers presented new data on the use of the fully human IL-17A inhibitor Cosentyx (secukinumab, Novartis) in moderate-to-severe psoriasis, at the 25th European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria, September 28 through October 2, 2016.
Nearly 100% of patients with clinically localized prostate cancer, detected by PSA testing, survive at an average 10 years’ follow-up, regardless of whether they had active monitoring, radical prostatectomy, or radiotherapy, according to new study results.
A report published by U.S. based market research company Grand View Research suggests the global skincare products market will reach $196.67 billion by 2024, up from an estimated $129.21 billion in 2015.
There are important differences in and misconceptions about the prevalence, clinical presentation and treatment of skin of color versus Caucasian psoriasis patients. Dermatologist Andrew F. Alexis, M.D., M.P.H., share his insight about what dermatologists need to know when treating psoriasis skin of color patients.
Although pediatric atopic dermatitis and acne have some similarities among children with skin of color and lighter-skinned children, there are important differences when these common skin conditions affect darker skin types.
Domestic water hardness and chlorine have been suggested as important risk factors for atopic dermatitis (AD). One recent study by researchers from Kings College London, United Kingdom, explored the potential associations between domestic water calcium carbonate (CaCO3) and chlorine concentrations in home water systems, damage to the skin's natural barrier, and incidences of AD in infancy.